Internal Medicine, Medical Oncology · Effingham, IL
NPI
1710076567
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
905 Medical Park Dr
Effingham, IL, 62401
Phone (217) 342-2066
Groups this clinician bills Medicare through
Medicare paid, 2024
$11.1M
753,539 services
Medicare patients, 2024
1,147
Average age 75
Drug cost, 2024
$8.6M
3,993 prescriptions
Company payments, 2025
$1,160
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Philip A Dy was code J1439 (injection, ferric carboxymaltose, 1 mg), 231,000 times for 137 patients. In total Philip A Dy billed 753,539 services in 209 codes, and Medicare paid $11.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 231,000 | 137 | $0.87 | $202K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 39,600 | 29 | $44.76 | $1.8M |
| J9299 Injection, nivolumab, 1 mg | Office | 29,800 | 12 | $24.60 | $733K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 28,500 | 13 | $0.06 | $1,631 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 26,600 | 155 | $0.10 | $2,723 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 22,860 | 13 | $38.99 | $891K |
| J0185 Injection, aprepitant, 1 mg | Office | 19,630 | 25 | $1.33 | $26K |
| J9267 Injection, paclitaxel, 1 mg | Office | 14,878 | 16 | $0.08 | $1,173 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 14,431 | 35 | $6.30 | $91K |
| J0897 Injection, denosumab, 1 mg | Office | 12,720 | 40 | $20.68 | $263K |
| J1930 Injection, lanreotide, 1 mg | Office | 12,240 | 11 | $38.55 | $472K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 8,830 | 21 | $35.54 | $314K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 8,442 | 106 | $0.08 | $651 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 6,600 | 18 | $20.67 | $136K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 4,920 | 69 | $0.70 | $3,444 |
By year: 2022 $9.7M for 658,668 services; 2023 $10.1M for 652,864 services; 2024 $11.1M for 753,539 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80053 Clinical Chemistry | 2,685 | 691 | $10.35 | $28K |
| 83735 Clinical Chemistry | 2,431 | 665 | $6.57 | $16K |
| 36415 Venipuncture Blood Collection | 2,427 | 667 | $8.65 | $21K |
| 83615 Clinical Chemistry | 2,385 | 668 | $5.92 | $14K |
| 85007 Blood Count | 1,675 | 468 | $3.72 | $6,231 |
| 85027 Blood Count | 1,675 | 468 | $6.34 | $11K |
| 85025 Blood Count | 1,327 | 523 | $7.61 | $10K |
| 82784 Immunoassay | 861 | 106 | $9.11 | $7,846 |
| 88185 Surgical Pathology Examination | 833 | 27 | $16.83 | $14K |
| 82378 Clinical Chemistry | 785 | 266 | $18.55 | $15K |
Medicare prescription drug claims, 2024
In 2024, the drug Philip A Dy prescribed most often to Medicare patients was Anastrozole, with 441 prescriptions and refills. In total Philip A Dy wrote 3,993 Medicare prescriptions that cost $8.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 441 | 936 | 96 | $7,507 |
| Prednisone Generic | 265 | 319 | 51 | $1,086 |
| Prochlorperazine Maleate Generic | 204 | 204 | 138 | $2,095 |
| Abiraterone Acetate Generic | 145 | 145 | 19 | $293K |
| Ondansetron Hcl Generic | 123 | 125 | 78 | $2,028 |
| Eliquis Apixaban | 117 | 174 | 21 | $97K |
| Tamoxifen Citrate Generic | 112 | 226 | 25 | $2,158 |
| Levothyroxine Sodium Generic | 109 | 244 | 26 | $1,148 |
| Pantoprazole Sodium Generic | 103 | 165 | 22 | $754 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 101 | 101 | 25 | $2,043 |
| Hydroxyurea Generic | 97 | 252 | 28 | $1,876 |
| Dexamethasone Generic | 95 | 114 | 33 | $1,339 |
| Acyclovir Generic | 88 | 139 | 17 | $1,182 |
| Potassium Chloride Generic | 87 | 158 | 18 | $1,035 |
| Ondansetron Odt Ondansetron | 82 | 82 | 60 | $579 |
Brand drugs: 705 claims; generic drugs: 3,288 claims; opioid claims: 198.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Philip A Dy $1,160 ($1,160 in general payments such as food, travel and fees) from 25 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $144.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 8 | $144 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $135 |
| Pfizer Inc. PFE | 5 | $112 |
| GlaxoSmithKline, LLC. GSK | 6 | $102 |
| Amneal Pharmaceuticals LLC AMRX | 3 | $82.84 |
| Array Biopharma Inc PFE | 3 | $55.01 |
| Celgene Corporation BMY | 3 | $43.6 |
| Iovance Biotherapeutics, Inc. IOVA | 2 | $41.62 |
| Merck Sharp & Dohme LLC MRK | 2 | $39.99 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39.49 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.